~~<i id='CE3544DC6F'><strike id='CE3544DC6F'><tt id='CE3544DC6F'><pre id='CE3544DC6F'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

comprehensive

author：knowledge 2025-09-29 01:38:17 - browse：7121

LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

The deal includes up to another $400 million in payments if certain milestones are met.

Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Letters to First Opinion on caregivers, digital health, and more

focus

explore

leisure time

entertainment

explore

ChrisBoshoff,farright,speakingatapanelwith,fromleft,MatthewHerperofSTAT,KenKeller,LeviGarraway,andSu

WSS

Coloradans with cystic fibrosis could lose access to Trikafta

Inari Medical to buy amputation prevention company LimFlow

Key Senate panel to consider PBM, drug pricing reform package

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

Key Senate panel to consider PBM, drug pricing reform package

knowledge

comprehensive

focus

Psychedelics group wrestles with new pharma identity

Brain injuries and the importance of a second opinion

Guidelines to prevent youth baseball injuries need more muscle

Letters to First Opinion on caregivers, digital health, and more

Virginia high school admissions case could be legal follow

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

Sports medicine is finally prioritizing gender equality

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

At least 13 dead in Texas as scorching temps continue

After Sarepta trial failure, Duchenne families brace for more debate

explore

How neuroscience research could help beat back brain cancer

Innovation in antibiotics is ailing. 'Brain drain' may kill it

See how much Covid

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

Coloradans with cystic fibrosis could lose access to Trikafta

Kaiser's Risant Health gobbled up Geisinger. Who is next?

explore

leisure time

entertainment

explore